Across TCGA pan-cancer cohorts, BRICD5 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated BRICD5 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher BRICD5 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated BRICD5 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

COAD and UCEC are the cancer types where BRICD5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	All	0.134	0.794	<.001	12	view →
UCEC	DFS	Median	All	1.000	0.635	.039	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: BRICD5 tumor-vs-normal RNA expression · all BRICD5 data types